Why is Transgene Biotek falling/rising?

As of 09-Sep, Transgene Biotek Ltd is experiencing a decline in its stock price, currently at 3.69, which reflects a decrease of 0.31 or 7.75%. The stock has underperformed significantly today, falling by 7.74% compared to its sector. Additionally, it is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The delivery volume has also seen a drastic drop of 62.91% against the 5-day average, indicating a falling investor participation. Over the past week, the stock has decreased by 1.34%, and its performance over the last month shows a substantial decline of 21.15%. Year-to-date, the stock has plummeted by 45.97%, while its one-year return is down by 56.28%. There are no positive or negative factors available to provide further context on the stock's recent movement.
In the broader market context, the stock's performance has been notably poor compared to the benchmark Sensex, which has gained 1.18% over the past week and 1.56% over the past month. While the Sensex has shown a year-to-date increase of 3.79%, Transgene Biotek's significant declines highlight a stark contrast in performance. The stock's long-term returns also reflect a troubling trend, with a 3-year return of 6.65% compared to the Sensex's 35.64%, and a 5-year return of -23.28% against the benchmark's impressive 112.34%. This underperformance in both short-term and long-term metrics suggests a challenging environment for Transgene Biotek Ltd amidst a generally positive market backdrop.